Murat Kalayoglu's guest appearances

Murat Kalayoglu

BioTalk with Rich Bendis

Business Of Biotech

Kurt Newman

James Taylor

Matt Brady

Mike Gill

Leslie Williams

Lisa Johnson

Sarah Howell

George Davis

Amit Kumar

Jeff Stein

Andrew Lees

Jim Hughes

James Thomas

Carolyn Yarina

Paul Rennie

OwlTail

Cartesian Therapeutics

Cartesian Therapeutics President &amp; Chief Executive Officer, Murat Kalayoglu, MD, PhD, Returns to BioTalk to provide an update since his last visit on their cell and gene therapies, as well as fundraising successes.

Cartesian Therapeutics President &amp; Chief Executive Officer, Murat Kalayoglu, MD, PhD, Returns to BioTalk to provide an update since his last visit on their cell and gene therapies, as well as fundraising successes.

Murat Kalayoglu, MD, PhD - Cartesian Therapeutics (EP.89)

Cartesian President &amp; CEO Murat Kalayoglu, M.D., Ph.D.  has led three of his company's six autoimmune, oncology, and respiratory candidates through Phase I/II clinical trials and two more of them are on the cusp of entering Phase I this year.  With so many programs in and entering the clinic, he's a great choice for a conversation on GMP expectations for phase I first-in-human trials. Glean insight from Cartesian's experiences and learn about the company's novel approach to RNA-engineered cell therapies for oncology and beyond on this episode of The Business of Biotech. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Cartesian President &amp; CEO Murat Kalayoglu, M.D., Ph.D.  has led three of his company's six autoimmune, oncology, and respiratory candidates through Phase I/II clinical trials and two more of them are on the cusp of entering Phase I this year.  With so many programs in and entering the clinic, he's a great choice for a conversation on GMP expectations for phase I first-in-human trials. Glean insight from Cartesian's experiences and learn about the company's novel approach to RNA-engineered cell therapies for oncology and beyond on this episode of The Business of Biotech. Subscribe to the NEW #BusinessofBiotech newsletter at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a> for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a>!

RNA-Engineered Cell Therapy with Cartesian's Dr. Murat Kalayoglu

Cartesian Therapeutics’ President &amp; CEO Murat Kalayoglu, MD, Ph.D., guests on BioTalk from the BioHealth Capital Region Investor Conference to talk about developing novel cell and gene therapies, building his company in the region, and also being an investor.

Cartesian Therapeutics’ President &amp; CEO Murat Kalayoglu, MD, Ph.D., guests on BioTalk from the BioHealth Capital Region Investor Conference to talk about developing novel cell and gene therapies, building his company in the region, and also being an investor.

Dr. Murat Kalayoglu, MD, Ph.D., Cartesian Therapeutics (EP.43)